Skip to main content
148 search results for:

Early stage breast cancer 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 25-07-2022 | Breast cancer | News | Article

    Postmenopausal hormone therapy may be feasible for early-stage breast cancer survivors

    Postmenopausal women who use vaginal estrogen therapy or menopausal hormone therapy after surgery for early-stage, estrogen receptor-positive breast cancer may not have an increased risk for recurrence or death, suggest Danish investigators.

  2. 21-09-2021 | ESMO 2021 | Conference coverage | Article

    Extended letrozole may improve long-term survival of early-stage breast cancer

    Extending adjuvant aromatase inhibitor therapy with letrozole to 5 years improves survival among women with hormone receptor-positive breast cancer who have already received 2 to 3 years of tamoxifen, shows the phase 3 GIM4 trial.

  3. play
    19-12-2020 | SABCS 2020 | Conference coverage | Video

    Adjuvant CDK4/6 inhibition in early-stage HR-positive breast cancer

    Ruth O'Regan comments on the monarchE trial of abemaciclib and the PENELOPE-B and PALLAS trials of palbociclib investigating CDK4/6 inhibitor therapy in the adjuvant, hormone receptor-positive, early-stage breast cancer setting (6:35).

  4. 06-10-2020 | ESMO 2020 | Conference coverage | Article
    News in brief

    pCR predicts 5-year survival for early-stage, HR-positive, HER2-positive breast cancer

    Pathologic complete response is significantly associated with 5-year survival outcomes for early-stage breast cancer patients with hormone receptor-positive, HER2-positive disease, shows research reported at the ESMO Virtual Congress 2020.

  5. 19-05-2020 | Breast cancer | News | Article

    TAILORx sheds light on cognitive decline in early-stage breast cancer

    An analysis of the TAILORx trial has revealed early, but not sustained, cognitive decline among breast cancer patients treated with adjuvant chemoendocrine therapy relative to endocrine therapy alone.

  6. 11-06-2020 | ASCO 2020 | Conference coverage | Article

    No survival gain with early local therapy for de novo stage IV breast cancer

    Individuals who present with metastatic breast cancer do not experience improvement in overall survival or other outcomes with early locoregional therapy for an intact primary tumor, according to ECOG-ACRIN 2108 trial findings.

  7. 04-01-2019 | Supportive care | Article

    Cognitive effects of adjuvant endocrine therapy in older women treated for early-stage breast cancer: a 1-year longitudinal study

    Underwood EA et al. Support Care Cancer 2019; 27: 3035. doi:10.1007/s00520-018-4603-5

  8. 06-11-2017 | Triple-negative breast cancer | Article

    Role of Platinum in Early-Stage Triple-Negative Breast Cancer

    La Belle A et al. Curr Treat Options in Oncol 2017; 18: 68. doi:10.1007/s11864-017-0506-9

  9. 18-12-2017 | Breast cancer | Article

    IL-6 and IL-10 are associated with good prognosis in early stage invasive breast cancer patients

    Ahmad N et al. Cancer Immunol Immunother 2017. doi:10.1007/s00262-017-2106-8

  10. 14-11-2017 | Breast cancer | Article

    Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up

    Ohnstad HO et al. Breast Cancer Res 2017; 19: 120. doi:10.1186/s13058-017-0911-9

  11. 18-05-2018 | HER2-positive breast cancer | Article

    Impact of timing of trastuzumab initiation on long-term outcome of patients with early-stage HER2-positive breast cancer: the “one thousand HER2 patients” project

    Gullo G et al.  Br J Cancer 2018. doi:10.1038/s41416-018-0114-x

  12. 22-11-2016 | Breast cancer | Article

    Adjuvant chemotherapy and HER-2-directed therapy for early-stage breast cancer in the elderly

    An overview of the assessment tools for clinicians when determining whether elderly patients are ‘fit’ for chemotherapy and discussion of the use of chemotherapy and trastuzumab in this population. Br J Cancer  2017; 116: 4–9. doi:10.1038/bjc.2016.360

  13. 05-06-2023 | Breast cancer | Conference coverage | Article
    ASCO 2023

    Adjuvant ribociclib reduces recurrence risk in early breast cancer

    Supplementing endocrine therapy with ribociclib significantly decreases the relapse risk in people with hormone receptor-positive, HER2-negative, early breast cancer.

  14. 01-03-2023 | Breast cancer | News | Article

    PRIME II ‘extremely reassuring’ on radiotherapy omission in older women with early breast cancer

    The 10-year data from the PRIME II trial suggest that radiotherapy after breast-conserving surgery can be omitted for women aged 65 years or older with low-risk, hormone receptor-positive early breast cancer.

  15. 04-11-2022 | Breast cancer | News | Article

    Concurrent olaparib, radiotherapy well tolerated in early-stage TNBC

    The phase 1 RadioPARP trial points to the tolerability of administering olaparib concomitantly with adjuvant radiotherapy in patients with early-stage triple-negative breast cancer and residual disease after neoadjuvant chemotherapy.

  16. 06-10-2022 | Breast cancer | News | Article

    Meta-analysis shows link between margin involvement and poor breast cancer outcomes

    Involved or close pathologic margins after breast conserving surgery are associated with an increased risk for distant recurrence and mortality in women with early-stage invasive breast cancer, indicates a meta-analysis.

  17. 09-12-2022 | SABCS 2022 | Conference coverage | Article

    Encouraging data for neoadjuvant T-DXd in HER2-low early breast cancer

    Trastuzumab deruxtecan has demonstrated promising efficacy and tolerability in the neoadjuvant treatment of HER2-low, hormone receptor-positive early breast cancer in the TRIO-US B-12 TALENT trial.

  18. 08-12-2022 | SABCS 2022 | Conference coverage | Article

    monarchE 4-year results show abemaciclib benefit is maintained beyond treatment completion

    The 4-year results from monarchE indicate that the invasive disease-free survival gain offered by adjuvant abemaciclib in people with high-risk, hormone receptor-positive, HER2-negative, early breast cancer is maintained even after the 2-year treatment period.

  19. 26-10-2022 | Breast cancer | News | Article

    Minimal access breast surgery ‘valid’ option for early breast cancer

    Minimal access breast surgery offers comparable long-term outcomes to conventional surgery for women with stage 0–III breast cancer, show the results of a propensity-matched, retrospective cohort study.

  20. 03-10-2022 | Breast cancer | News | Article

    High IL-6, CRP may predict increased frailty after breast cancer chemotherapy

    Clinically fit older women with early breast cancer are more likely to experience a chemotherapy-induced decline in frailty status if they have high pretreatment levels of interleukin-6 and C-reactive protein, research shows.

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.